Basilea Pays US$37 M Upfront for Antifungal from Pfizer’s Amplyx
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 11 (Table of Contents)
Published: 17 Nov-2023
DOI: 10.3833/pdr.v2023.i11.2836 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In another move to bolster its anti-infective pipeline, Basilea has agreed to acquire anti-fungal, fosmanogepix, from Ampylyx Pharmaceuticals, an affiliate of Pfizer...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS